Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial

JAMA

Volumn 297, Issue 15, 2007, Pages 1675-1682

  Tardif, Jean Claude ^a   Grégoire, Jean ^a   L'Allier, Philippe L ^a   Ibrahim, Reda ^a   Lespérance, Jacques ^a   Heinonen, Therese M ^a   Kouz, Simon ^b   Berry, Colin ^a   Basser, Russell ^c   Lavoie, Marc André ^a   Guertin, Marie Claude ^a   Rodés Cabau, Josep ^d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b Centre Hospitalier Regional de Lanaudiere   (Canada)

^c CSL LIMITED   (Australia)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CSL 111; HIGH DENSITY LIPOPROTEIN; PLACEBO; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTHRALGIA; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BRAIN DISEASE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART ARREST; HEART INFARCTION; HUMAN; HYPOTENSION; INTRAVASCULAR ULTRASOUND; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STROKE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VOMITING;

EID: 34247397359     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.15.jpc70004     Document Type: Article

References (32)

1. 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
3. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med. 1977;62:707-714.
4. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial.Am J Cardiol. 2000;86(12A):19L-22L.
5. Krause BR, Auerbach BJ. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr Opin Investig Drugs. 2001;2:375-381.
6. Nissen SE, Tsunodo T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA. 2003;290:2292-2300.
7. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
8. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluidandstimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586-1593.
9. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944-2948.
10. Lerch PG, Fortsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 1996;71:155-164.
11. Côte G, Tardif JC, Lesperance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation. 1999;99:30-35.
12. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-1565.
13. Tardif JC, Gregoire J, Lesperance J, et al. Design features of the avasimibe and progression of coronary lesions assessed by intravascular ultrasound (APLUS) clinical trial. Am Heart J. 2002;144:589-596.
14. Tardif JC, Gregoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 2003;107:552-558.
15. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004;110:3372-3377.
16. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS): a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37:1478-1492.
17. Lee HS, Tardif JC, Harel F, et al. Effects of plaque composition on vascular remodeling after angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol. 2002;18:271-275.
18. Tardif JC, Côté G, Lespérance J, et al; MVP Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997;337:365-372.
19. Palmer ND, Northridge D, Lessells A, et al. In vitro analysis of coronary atheromatous lesions by intravascular ultrasound: reproducibility and histological correlations of lesion morphology. Eur Heart J. 1999;20:1701-1708.
20. Schartl M, Bocksch W, Koschyk DH, et al; GAIN Investigators. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104:387-392.
21. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
22. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
23. Waters D, Crave TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
24. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
25. Schwartz GG, Olsson AG, Ezekowitz MD, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
26. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C-the importance of raising HDL-C. Curr Med Res Opin. 2002;18:36-44.
27. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 2002;161:245-254.
28. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13-27.
29. Libby P. Managing the risk of atherosclerosis: the role of high-density lipoprotein. Am J Cardiol. 2001;88(12A):3N-8N.
30. Packard C, Nunn A, Hobbs R; Future Forum Editorial Board. High density lipoprotein: guardian of the vascular system? Int J Clin Pract. 2002;56:761-771.
31. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol. 2003;92(4A):42J-49J.
32. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27:257-260.